Hostname: page-component-686fd747b7-8z4zl Total loading time: 0 Render date: 2025-02-13T14:32:11.006Z Has data issue: false hasContentIssue false
  • English
  • Français

Real-world effectiveness of long-acting injectable antipsychotics to reduce 90-day and annual readmission in psychotic disorders: insights from a state psychiatric hospital

Published online by Cambridge University Press:  03 May 2021

Rikinkumar S. Patel Open the ORCID record for Rikinkumar S. Patel [Opens in a new window]  and
William E. Tankersley
Rikinkumar S. Patel*
Affiliation:
Department of Psychiatry, Griffin Memorial Hospital, Norman, Oklahoma, USA Department of Psychiatry and Behavioral Science, Oklahoma State University, Tulsa, Oklahoma, USA
William E. Tankersley
Affiliation:
Department of Psychiatry, Griffin Memorial Hospital, Norman, Oklahoma, USA Department of Psychiatry and Behavioral Science, Oklahoma State University, Tulsa, Oklahoma, USA
*
*Author for correspondence: Rikinkumar S. Patel, MD, MPH Email: dr.rknpatel@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

To evaluate the effectiveness of long-acting injectable antipsychotics (LAI-a) in reducing the 90-day and annual readmission rates in schizophrenia inpatients.

Methods

We conducted a cross-sectional study and included 180 adult patients with psychotic disorders discharged from 2018 to 2019 at a state psychiatric hospital. Descriptive statistics were used to measure the differences between the readmit and nonreadmit cohorts. Logistic regression model was used to measure the odds ratio (OR) for 90-day and annual readmission and was controlled for potential readmission risk factors.

Results

A lower proportion of patients receiving LAI-a were readmitted within 90-day (28.6%) and 1-year (32.4%) periods. Patients receiving LAI-a had lower odds of association for 90-day (OR 0.36, 95% confidence intervals [CI] 0.139-0.921) and annual (OR 0.35, 95% CI 0.131-0.954) readmissions compared to those discharged on oral antipsychotics. A higher proportion of inpatients who received fluphenazine LAI had 90-day (25%) and annual (18.2%) readmissions compared to other LAI-a.

Conclusion

Utilization of LAI-a in patients with psychotic disorders can decrease both 90-day and annual psychiatric readmissions by 64% to 65%. Physicians should prefer LAI-a to reduce the readmission rate and improve the quality of life, and decrease the healthcare-related financial burden.

Keywords

Annual readmissionlong-acting injectable antipsychoticsreadmission ratepotential readmission risk factorsrecurrent schizophrenia patientshealthcare-related financial burden
Type
Original Research
Information
CNS Spectrums , Volume 27 , Issue 5 , October 2022 , pp. 626 - 633
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Robinson, D, Woerner, MG, Alvir, JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. doi:10.1001/archpsyc.56.3.241.CrossRefGoogle ScholarPubMed
Lieberman, JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68(2):e04. doi:10.4088/jcp.0207e04.CrossRefGoogle ScholarPubMed
Lafeuille, MH, Laliberte-Auger, F, Lefebvre, P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13:221. doi:10.1186/1471-244X-13-221.CrossRefGoogle ScholarPubMed
Gadkari, AS, McHorney, CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98. doi:10.1186/1472-6963-12-98.CrossRefGoogle Scholar
Keepers, GA, Fochtmann, LJ, Anzia, JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.177901.CrossRefGoogle ScholarPubMed
Gerlach, J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol. 1995;9(Suppl 5):17–20. doi:10.1097/00004850-199501005-00004.CrossRefGoogle ScholarPubMed
Correll, CU, Citrome, L, Haddad, PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24. doi:10.4088/JCP.15032su1.CrossRefGoogle ScholarPubMed
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213. doi:10.1093/schbul/sbs150.CrossRefGoogle ScholarPubMed
Kishimoto, T, Nitta, M, Borenstein, M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. doi:10.4088/JCP.13r08440.CrossRefGoogle ScholarPubMed
Lorine, K, Goenjian, H, Kim, S, et al. Risk factors associated with psychiatric readmission. J Nerv Ment Dis. 2015;203(6):425–430. doi:10.1097/NMD.0000000000000305.CrossRefGoogle ScholarPubMed
Zhang, J, Harvey, C, Andrew, C. Factors associated with length of stay and the risk of readmission in an acute psychiatric inpatient facility: a retrospective study. Aust N Z J Psychiatry . 2011;45(7):578–585. doi:10.3109/00048674.2011.585452.CrossRefGoogle Scholar
Mejia de Grubb, MC, Salemi, JL, Gonzalez, SJ, et al. Opioid, cocaine, and amphetamine use disorders are associated with higher30-day inpatient readmission rates in the United States. Subst Abus. 2020;41(3):365–374. doi:10.1080/08897077.2019.1635964.CrossRefGoogle ScholarPubMed
Patel, RS, Sreeram, V, Vadukapuram, R, et al. Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study. Schizophr Res. 2020;224:40–44. doi:10.1016/j.schres.2020.11.002.CrossRefGoogle ScholarPubMed
Hamilton, JE, Passos, IC, de Azevedo Cardoso, T, et al. Predictors of psychiatric readmission among patients with bipolar disorder at an academic safety-net hospital. Aust N Z J Psychiatry . 2016;50(6):584–593. doi:10.1177/0004867415605171.CrossRefGoogle ScholarPubMed
Monnelly, EP. Instability before discharge and previous psychiatric admissions as predictors of early readmission. Psychiatr Serv. 1997;48(12):1584–1586. doi:10.1176/ps.48.12.1584.Google ScholarPubMed
Swett, C. Symptom severity and number of previous psychiatric admissions as predictors of readmission. Psychiatr Serv. 1995;46(5):482–485. doi:10.1176/ps.46.5.482.Google ScholarPubMed
Bockmann, V, Lay, B, Seifritz, E, et al. Patient-level predictors of psychiatric readmission in substance use disorders. Front Psychiatry. 2019;10:828. doi:10.3389/fpsyt.2019.00828.CrossRefGoogle ScholarPubMed
Desai, R, Nayak, R. Effects of medication nonadherence and comorbidity on health resource utilization in schizophrenia. J Manag Care Spec Pharm. 2019;25(1):37–46. doi:10.18553/jmcp.2019.25.1.037.Google Scholar
Andrews, CE, Baker, K, Howell, CJ, et al. Risk of hospitalization due to medication nonadherence identified through EMRS of patients with psychosis. Psychiatr Serv. 2017;68(8):847–850. doi:10.1176/appi.ps.201600334.CrossRefGoogle ScholarPubMed
Whitehead, C, Moss, S, Cardno, A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002;2:CD002305. doi:10.1002/14651858.CD002305.Google Scholar
Taipale, H, Mehtala, J, Tanskanen, A, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia—a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387. doi:10.1093/schbul/sbx176.CrossRefGoogle ScholarPubMed
MacEwan, JP, Kamat, SA, Duffy, RA, et al. Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv. 2016;67(11):1183–1188. doi:10.1176/appi.ps.201500455.CrossRefGoogle ScholarPubMed
Chou, F, Reome, E, Davis, P. Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder. Ment Health Clin. 2016;6(5):254–259. doi:10.9740/mhc.2016.09.254.CrossRefGoogle ScholarPubMed
Kim, HO, Seo, GH, Lee, BC. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry. 2020;19:1. doi:10.1186/s12991-019-0254-2.CrossRefGoogle ScholarPubMed
Maestri, TJ, Mican, LM, Rozea, H, et al. Do long-acting injectable antipsychotics prevent or delay hospital readmission? Psychopharmacol Bull . 2018;48(3):8–15.Google ScholarPubMed
Lin, CH, Chen, FC, Chan, HY, et al. A comparison of long-acting injectable antipsychotics with oral antipsychotics on time to rehospitalization within 1 year of discharge in elderly patients with schizophrenia. Am J Geriatr Psychiatry. 2020;28(1):23–30. doi:10.1016/j.jagp.2019.08.005.CrossRefGoogle ScholarPubMed
Stone, JM, Roux, S, Taylor, D, et al. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse. Ther Adv Psychopharmacol. 2018;8(12):333–336. doi:10.1177/2045125318795130.CrossRefGoogle ScholarPubMed
Heeren, O, Dixon, L, Gavirneni, S, et al. The association between decreasing length of stay and readmission rate on a psychogeriatric unit. Psychiatr Serv. 2002;53(1):76–79. doi:10.1176/appi.ps.53.1.76.CrossRefGoogle ScholarPubMed
Hodgson, RE, Lewis, M, Boardman, AP. Prediction of readmission to acute psychiatric units. Soc Psychiatry Psychiatr Epidemiol. 2001;36(6):304–309. doi:10.1007/s001270170049.CrossRefGoogle ScholarPubMed